目前胰腺癌的有效治疗策略是彻底地手术切除联合辅助化疗或放疗。随机临床试验报道单纯手术患者中位生存期约为18个月,手术后联合吉西他滨辅助化疗患者中位生存期约为22个月。术后同步放化疗组生存效益较单纯手术组更明显,中位生存期分别为25个月和19个月。虽然这些治疗方案在总生存率方面差异无统计学意义,但可能会延迟复发时间。另外,对显微镜下切缘阳性(R1)患者的治疗有一定价值。 The current effective treatment strategy for pancreatic cancer is complete surgical resection combined with adjuvant chemotherapy or radiotherapy. The randomized clinical trial reported median survival of approximately 18 months in patients who underwent surgery alone and approximately 22 months after surgery in combination with gemcitabine adjuvant chemotherapy. The survival benefit of concurrent chemoradiotherapy group was more obvious than that of the simple operation group. The median survival time was 25 months and 19 months respectively. Although these treatments did not show statistically significant differences in overall survival, they may delay relapse. In addition, the treatment of patients with positive (R1) under the microscope has some value.